Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.70 |
| ▸ | CPA3 | P15088 | 3/20 | 0.68 |
| ▸ | CPA1 | P15085 | 7/20 | 0.64 |
| ▸ | FOLH1 | Q04609 | 3/20 | 0.64 |
| ▸ | CPB1 | P15086 | 1/20 | 0.61 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.61 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.56 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.56 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.56 |
| ▸ | MME | P08473 | 1/20 | 0.53 |
| ▸ | NAALAD2 | Q9Y3Q0 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6724759 | 0.88 | CYP1A2 (0.83) | CYP1A2CPA3CPA1FOLH1CPB1 | |
| SCHEMBL12494233 | 0.88 | CYP1A2 (0.83) | CYP1A2CPA3CPA1FOLH1CPB1 | |
| SCHEMBL19821208 | 0.88 | CYP1A2 (0.83) | CYP1A2CPA3CPA1FOLH1CPB1 | |
| SCHEMBL2121039 | 0.87 | FOLH1 (0.68) | CYP1A2CPA3CPA1FOLH1CPB1 | |
| SCHEMBL6869749 | 0.86 | FOLH1 (0.66) | CYP1A2CPA3CPA1FOLH1CPB1 | |
| Hydrochloric Acid SCHEMBL6717346 | 0.86 | CYP1A2 (0.79) | CYP1A2CPA3CPA1FOLH1CPB1 | |
| SCHEMBL11664393 | 0.84 | FOLH1 (0.79) | CYP1A2CPA3CPA1FOLH1CPB1 | |
| SCHEMBL3818360 | 0.84 | CYP1A2 (0.76) | CYP1A2CPA3CPA1FOLH1CPB1 | |
| SCHEMBL4611801 | 0.84 | CYP1A2 (0.76) | CYP1A2CPA3CPA1FOLH1CPB1 | |
| SCHEMBL4664822 | 0.83 | CYP1A2 (1.00) | CYP1A2CPA3CPA1FOLH1CPB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-104945309-B | New nitroso compound and application thereof as nitroxyl donors | 卡尔迪奥克斯尔制药公司 | 2019-06-04 | — | — | CN | disclosed |
| US-9732029-B2 | Nitroso compounds as nitroxyl donors and methods of use thereof | CARDIOXYL PHARMACEUTICALS, INC. (US) | 2017-08-15 | — | — | US | disclosed |
| US-9725402-B2 | Nitroso compounds as nitroxyl donors and methods of use thereof | CARDIOXYL PHARMACEUTICALS, INC. (US) | 2017-08-08 | — | — | US | disclosed |
| EP-3067352-A2 | NOVEL NITROSO COMPOUNDS AS NITROXYL DONORS AND METHODS OF USE THEREOF | Cardioxyl Pharmaceuticals Inc. (US) | 2016-09-14 | — | — | EP | disclosed |
| EP-2278975-B1 | NOVEL NITROSO COMPOUNDS AS NITROXYL DONORS AND METHODS OF USE THEREOF | CARDIOXYL PHARMACEUTICALS INC (US) | 2016-09-07 | — | — | EP | disclosed |
| CN-105646637-A | Abiraterone derivative, preparation method and medical applications thereof | 四川海思科制药有限公司 | 2016-06-08 | — | — | CN | disclosed |
| US-20160052862-A1 | NOVEL NITROSO COMPOUNDS AS NITROXYL DONORS AND METHODS OF USE THEREOF | CARDIOXYL PHARMACEUTICALS, INC. | 2016-02-25 | — | — | US | disclosed |
| CN-104945309-A | Novel nitroso compounds as nitroxyl donors and methods of use thereof | CARDIOXYL PHARMACEUTICALS INC | 2015-09-30 | — | — | CN | disclosed |
| CN-102076342-B | Novel nitroso compounds as nitroxyl donors and methods of use thereof | CARDIOXYL PHARMACEUTICALS INC | 2015-06-10 | — | — | CN | disclosed |
| US-20140336137-A1 | NOVEL NITROSO COMPOUNDS AS NITROXYL DONORS AND METHODS OF USE THEREOF | CARDIOXYL PHARMACEUTICALS, INC. | 2014-11-13 | — | — | US | disclosed |
| EP-0322926-B1 | Assays utilizing improved chemiluminescent esters, thioesters and amides | NICHOLS INST DIAGNOSTICS (US) | 1999-08-11 | — | — | EP | disclosed |
| EP-0916658-A1 | Assays utilizing improved chemiluminescent esters, thioesters and amides | Nichols Institute Diagnostics (US) | 1999-05-19 | — | — | EP | disclosed |
| US-5290936-A | Indicators or labels for antibodies or medical diagnosis | LONDON DIAGNOSTICS, INC. (US) | 1994-03-01 | — | — | US | disclosed |
| US-5284951-A | Aryl ester, thioester or amide of carboxylic acid substituted heterocyclic ring; quaternary compounds | LONDON DIAGNOSTICS, INC. (US) | 1994-02-08 | — | — | US | disclosed |
| US-5283334-A | Side-chain functional chemiluminescent labels and their conjugates, and assays therefrom | LONDON DIAGNOSTICS, INC. (US) | 1994-02-01 | — | — | US | disclosed |
| WO-1989006231-A1 | ASSAYS UTILIZING IMPROVED CHEMILUMINESCENT ESTERS, THIOESTERS AND AMIDES | LONDON DIAGNOSTICS, INC. (US) | 1989-07-13 | — | — | WO | disclosed |
| EP-0322926-A2 | Assays utilizing improved chemiluminescent esters, thioesters and amides | LONDON DIAGNOSTICS, INC. (US) | 1989-07-05 | — | — | EP | disclosed |
| US-4154840-A | Antihypertensive pipecolic acid derivatives | E. R. SQUIBB & SONS, INC. (US) | 1979-05-15 | — | — | US | disclosed |
| US-4105776-A | ANGIOTENSIN CONVERTING ENZYME INHIBITORS, HYPOTENSIVE AGENTS | E. R. SQUIBB & SONS, INC. (US) | 1978-08-08 | — | — | US | disclosed |
| US-4046889-A | HYPOTENSIVE AGENTS, ENZYME INHIBITORS, ANGIOTENSIN CONVERSION | E. R. SQUIBB & SONS, INC. (US) | 1977-09-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160052862-A1 | NOVEL NITROSO COMPOUNDS AS NITROXYL DONORS AND METHODS OF USE THEREOF | NOXO1, TNNI3, HAO2 | CYP1A2 2023/4885CPA3 4253/4885CPA1 4395/4885 |
| US-20140336137-A1 | NOVEL NITROSO COMPOUNDS AS NITROXYL DONORS AND METHODS OF USE THEREOF | NOXO1, TNNI3, HAO2 | CYP1A2 2023/4885CPA3 4253/4885CPA1 4395/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.